Clément Morgat
Publications
-
Comparative analysis of positron emitters for theranostic applications based on small bioconjugates highlighting 43Sc, 61Cu and 45Ti
EJNMMI Phys. 2024-11-22. 11(1)
10.1186/s40658-024-00699-z -
Membrane and Nuclear Absorbed Doses from 177Lu and 161Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting—A Monte Carlo Study
J Nucl Med. 2023-06-15. : jnumed.123.265509.
10.2967/jnumed.123.265509 -
Modular One-Pot Strategy for the Synthesis of Heterobivalent Tracers
ACS Med. Chem. Lett.. 2023-04-21.
10.1021/acsmedchemlett.3c00057 -
Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R
Cancers. 2023-04-18. 15(8) : 2345.
10.3390/cancers15082345 -
Design and preclinical evaluation of a novel apelin-based PET radiotracer targeting APJ receptor for molecular imaging of angiogenesis
Angiogenesis. 2023-03-27.
10.1007/s10456-023-09875-8 -
A proof of principle study using radiopharmaceuticals to quantify and localize container-content interactions in medical syringes
Sci Rep. 2023-02-15. 13(1)
10.1038/s41598-023-29923-z -
Design, Synthesis, and Biological Evaluation of the First Radio-Metalated Neurotensin Analogue Targeting Neurotensin Receptor 2
ACS Omega. 2023-02-10. 8(7) : 6994-7004.
10.1021/acsomega.2c07814 -
Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in patients with localized prostate cancer candidate for radical prostatectomy: a prospective, single arm, single center, phase II study
J Nucl Med. 2022-09-02. : jnumed.122.263889.
10.2967/jnumed.122.263889 -
Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors
Breast Cancer Res Treat. 2021-10-01.
10.1007/s10549-021-06402-5 -
68Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of (68Ga)Ga-RM2
Pharmaceutics. 2021-07-28. 13(8) : 1160.
10.3390/pharmaceutics13081160 -
In vitro and pilot in vivo imaging of 18 kDa translocator protein (TSPO) in inflammatory vascular disease.
EJNMMI Res. 2021-05-05. 11(1)
10.1186/s13550-021-00786-7 -
Silicon-Containing Neurotensin Analogues as Radiopharmaceuticals for NTS1-Positive Tumors Imaging
Bioconjugate Chem.. 2020-09-18.
10.1021/acs.bioconjchem.0c00419 -
68Ga-PSMA-617 compared with 68Ga-RM2 and 18F-FCholine PET/CT for the initial staging of high-risk prostate cancer
. .
10.1097/RLU0000000000002672 -
Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases
EJNMMI Phys. 2020-05-19. 7(1)
10.1186/s40658-020-00301-2 -
Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides
EJNMMI Res. 2020-03-02. 10(1)
10.1186/s13550-020-0612-8 -
Étude dosimétrique de préparations de médicaments radiopharmaceutiques au 68Ga
Médecine Nucléaire. 2019-10-01. 43(5-6) : 381-385.
10.1016/j.mednuc.2019.04.007 -
68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer
Clinical Nuclear Medicine. 2019-09-01. 44(9) : e535-e536.
10.1097/rlu.0000000000002672 -
Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples
EJNMMI Res. 2019-06-03. 9(1)
10.1186/s13550-019-0517-6 -
Early use of abiraterone and radium-223 in metastatic prostate cancer
The Lancet Oncology. 2019-05-01. 20(5) : e229.
10.1016/s1470-2045(19)30235-9 -
Radiopharmaceuticals targeting PSMA for imaging and/or therapy
Médecine Nucléaire. 2019-05-01. 43(3) : 284-286.
10.1016/j.mednuc.2019.04.003 -
Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases
IJMS. 2019-04-07. 20(7) : 1721.
10.3390/ijms20071721 -
Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples
PLoS ONE. 2019-01-15. 14(1) : e0210905.
10.1371/journal.pone.0210905 -
État actuel de l’utilisation en essais cliniques de molécules radiomarquées au 68Ga en France. Exemple du site de Bordeaux
Médecine Nucléaire. 2018-11-01. 42(6) : 428-431.
10.1016/j.mednuc.2018.08.003 -
Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists
J Nucl Med. 2017-10-06. 59(3) : 546-547.
10.2967/jnumed.117.202630 -
Somatostatin Antagonists for Radioligand Therapy of Nonendocrine Tumors
J Nucl Med. 2017-08-17. 59(3) : 544-544.
10.2967/jnumed.117.199158 -
Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging
Eur J Nucl Med Mol Imaging. 2017-03-10. 44(6) : 1095-1096.
10.1007/s00259-017-3667-7 -
Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors
J Nucl Med. 2017-03-09. 58(9) : 1401-1407.
10.2967/jnumed.116.188011 -
Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy
Journal of Nuclear Medicine. 2016-02-09. 57(5) : 759-764.
10.2967/jnumed.115.170423 -
Evaluation of 68Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1
Eur J Nucl Med Mol Imaging. 2016-01-28. 43(7) : 1258-1266.
10.1007/s00259-016-3319-3 -
Comparison between Three Promising ß-emitting Radionuclides, 67Cu, 47Sc and 161Tb, with Emphasis on Doses Delivered to Minimal Residual Disease
Theranostics. 2016-01-01. 6(10) : 1611-1618.
10.7150/thno.15132 -
A phantom-based method to standardize dose-calibrators for new β+-emitters
Nuclear Medicine Communications. 2015-02-01. 36(2) : 201-206.
10.1097/mnm.0000000000000227 -
Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors
Journal of Nuclear Medicine. 2014-09-04. 55(10) : 1650-1657.
10.2967/jnumed.114.142000 -
Gallium-68: Chemistry and Radiolabeled Peptides Exploring Different Oncogenic Pathways
Cancer Biotherapy and Radiopharmaceuticals. 2013-03-01. 28(2) : 85-97.
10.1089/cbr.2012.1244